Pilot and feasibility study: Comparative proteomic analysis by 2-DE MALDI TOF/TOF MS reveals 14-3-3 proteins as putative biomarkers of response to neoadjuvant chemotherapy in ER-positive breast cancer

Journal of Proteomics

Volumn 75, Issue 9, 2012, Pages 2745-2752

  Hodgkinson, Victoria C ^a   Agarwal, Vijay ^a,b,c   ELFadl, Dalia ^a,c   Fox, John N ^c   McManus, Penelope L ^c   Mahapatra, Tapan K ^c   Kneeshaw, Peter J ^c   Drew, Philip J ^a,b,c   Lind, Michael J ^a,b,c   Cawkwell, Lynn ^a,b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

14 3 3; Biomarkers; Breast cancer; Mass spectrometry; Neoadjuvant chemotherapy; Proteomics

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; ISOPROTEIN; PROTEIN 14 3 3; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

14-3-3 PROTEINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEASIBILITY STUDIES; FEMALE; HUMANS; NEOADJUVANT THERAPY; PILOT PROJECTS; RECEPTORS, ESTROGEN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860466128     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.03.049     Document Type: Article

References (43)

1. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature. 2000, 406:747-752.
2. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2001, 98:10869-10874.
3. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 2003, 100:8418-8423.
4. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast cancer research : BCR. 2010, 12:R68.
5. Bhargava R., Beriwal S., Dabbs D.J., Ozbek U., Soran A., Johnson R.R., et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer. 2010, 116:1431-1439.
6. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005, 11:5678-5685.
7. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007, 13:2329-2334.
8. Colleoni M., Viale G., Zahrieh D., Bottiglieri L., Gelber R.D., Veronesi P., et al. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Annals of Oncology. 2008, 19:465-472.
9. von Minckwitz G., Sinn H.-P., Raab G., Loibl S., Blohmer J.-U., Eidtmann H., et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Research. 2008, 10:R30.
10. Colleoni M., Bagnardi V., Rotmensz N., Gelber R., Viale G., Pruneri G., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Research and Treatment. 2009, 116:359-369.
11. Darb-Esfahani S., Loibl S., Muller B., Roller M., Denkert C., Komor M., et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer Research. 2009, 11:R69.
12. Kim S.I., Sohn J., Koo J.S., Park S.H., Park H.S., Park B.W. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Oncology. 2010, 79:324-330.
13. Huober J., von Minckwitz G., Denkert C., Tesch H., Weiss E., Zahm D., et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Research and Treatment. 2010, 124:133-140.
14. Precht L.M., Lowe K.A., Atwood M., Beatty J.D. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival. The Breast Journal. 2010, 16:362-368.
15. Straver M., Rutgers E., Rodenhuis S., Linn S., Loo C., Wesseling J., et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Annals of Surgical Oncology. 2010, 17:2411-2418.
16. Straver M., Glas A., Hannemann J., Wesseling J., van de Vijver M., Rutgers E., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010, 119:551-558.
17. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005, 23:7265-7277.
18. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009, 15:68-74.
19. Naoi Y., Kishi K., Tanei T., Tsunashima R., Tominaga N., Baba Y., et al. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer. 2011, 117:3682-3690.
20. Lin Y., Lin S., Watson M., Trinkaus K., Kuo S., Naughton M., et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 2010, 123:691-699.
21. Hodgkinson V.C., Eagle G.L., Drew P.J., Lind M.J., Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer letters. 2010, 294:13-24.
22. Chuthapisith S, Layfield, R., Kerr, I., Hughes, C., Eremin, O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol. 2007;30:1545-51.
23. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncology research. 2007, 16:497-506.
24. Fu Z., Fenselau C. Proteomic evidence for roles for nucleolin and poly[ADP-ribosyl] transferase in drug resistance. Journal of proteome research. 2005, 4:1583-1591.
25. Liu Y., Liu H., Han B., Zhang J.-T. Identification of 14-3-3σ as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer research. 2006, 66:3248-3255.
26. Hodgkinson V.C., ELFadl D., Agarwal V., Garimella V., Russell C., Long E.D., et al. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. J Proteomics. 2012, 75:1276-1283.
27. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute. 2000, 92:205-216.
28. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-247.
29. Mariman E.C. 2DE-proteomics meta-data indicate the existence of distinct cellular stress-responsive mechanisms. Expert Rev Proteomics. 2009, 6:337-339.
30. Petrak J., Ivanek R., Toman O., Cmejla R., Cmejlova J., Vyoral D., et al. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics. 2008, 8:1744-1749.
31. Ponomarenko E., Lisitsa A., Petrak J., Moshkovskiǐ S., Archakov A. Identification of differentially expressed proteins using automatic meta-analysis of proteomics-related articles. Biomed Khim. 2009, 55:5-14.
32. Wang P., Bouwman F.G., Mariman E.C.M. Generally detected proteins in comparative proteomics - a matter of cellular stress response?. Proteomics. 2009, 9:2955-2966.
33. Hodgkinson V.C., Elfadl D., Drew P.J., Lind M.J., Cawkwell L. Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. Journal of Proteomics. 2011, 74:698-703.
34. Sluchanko N.N., Gusev N.B. 14-3-3 proteins and regulation of cytoskeleton. Biochemistry Biokhimiia. 2010, 75:1528-1546.
35. Tzivion G., Gupta V.S., Kaplun L., Balan V. 14-3-3 proteins as potential oncogenes. Seminars in Cancer Biology. 2006, 16:203-213.
36. Robinson D.N. 14-3-3, an integrator of cell mechanics and cytokinesis. Small GTPases. 2010, 1:165-169.
37. Zhou Q., Kee Y.S., Poirier C.C., Jelinek C., Osborne J., Divi S., et al. 14-3-3 coordinates microtubules, Rac, and myosin II to control cell mechanics and cytokinesis. Current biology : CB. 2010, 20:1881-1889.
38. Masters S.C., Subramanian R.R., Truong A., Yang H., Fujii K., Zhang H., et al. Survival-promoting functions of 14-3-3 proteins. Biochem Soc Trans. 2002, 30:360-365.
39. Sunayama J., Tsuruta F., Masuyama N., Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. The Journal of cell biology. 2005, 170:295-304.
40. Memos N., Kataki A., Chatziganni E., Nikolopoulou M., Skoulakis E., Consoulas C., et al. Alternations of 14-3-3 theta and beta protein levels in brain during experimental sepsis. Journal of neuroscience research. 2011, 89:1409-1418.
41. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochimica et biophysica acta. 2011.
42. Wang B., Liu K., Lin H.-Y., Bellam N., Ling S., Lin W.-C. 14-3-3{tau} regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol. 2010, 30:1508-1527.
43. Vazquez A, Grochola, L., Bond, E., Levine, A., Taubert, H., Muller, T., Wurl, P., Bond, G. Chemosensitivity Profiles Identify Polymorphisms in the p53 Network Genes 14-3-3 tau and CD44 That Affect Sarcoma Incidence and Survival. Molecular and Cellular Pathobiology. 2010;70:172-80.